|
- Standard-of-care systemic therapy with or without stereotactic body . . .
Oligoprogression in patients with metastatic NSCLC could be effectively treated with SBRT plus standard of care, leading to more than a four-times increase in progression-free survival compared with standard of care only
- Stereotactic Body Radiotherapy for the Management of Early-Stage Non . . .
This report triggered a wave of trials and clinical studies of SBRT, particularly as it was applied to lung tumors (both primary and metastatic) in patients who were not surgical candidates
- Stereotactic Body Radiation Therapy for Primary Lung Cancer and . . .
SBRT is now considered a standard-of-care treatment for inoperable early-stage non-small cell lung cancer and lung metastases, and therefore extrapolation beyond this limited foundational patient population remains an active source of interest
- Combining stereotactic body radiotherapy with immunotherapy in stage IV . . .
Here, we review the current clinical evidence supporting the combination of SBRT with immunotherapy in the treatment of metastatic NSCLC Also, we discuss the current controversies and areas for further exploration associated with this treatment strategy
- Comparison of Response and Survival in Patients of Metastatic Non-Small . . .
In the current study we have assessed response and survival in metastatic NSCLC between groups that received SBRT and I-SBRT Prospectively, 25 patients with metastatic recurrent NSCLC recruited between Jan 2017 to Feb 2020, who underwent SBRT and systemic treatment were included in the study
- Trends and costs of stereotactic body radiation therapy in metastatic . . .
Background: The purpose of this study is to describe stereotactic body radiation therapy (SBRT) use, outcomes, hospitalizations and costs compared to patients receiving chemotherapy among patients with metastatic non-small cell lung cancer (NSCLC)
- A Phase II Trial of Stereotactic Body Radiotherapy (SBRT) in Patients . . .
We conducted a single-arm, Phase II trial of SBRT to residual sites of original disease in patients (pts) with oncogene-driven, metastatic NSCLC on first line TKI
- Stereotactic body radiotherapy improves the survival of patients with . . .
The aim of the study was to evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for pulmonary lesions in oligometastatic non‐small cell lung cancer (NSCLC) patients, to explore prognostic factors of progression‐free survival
|
|
|